Inhibikase Therapeutics Inc. (IKT): Price and Financial Metrics

Inhibikase Therapeutics Inc. (IKT): $2.64

0.11 (+4.35%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add IKT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#261 of 357

in industry

IKT Price/Volume Stats

Current price $2.64 52-week high $3.82
Prev. close $2.53 52-week low $0.80
Day low $2.54 Volume 85,900
Day high $2.73 Avg. volume 188,547
50-day MA $1.59 Dividend yield N/A
200-day MA $1.79 Market Cap 19.70M

IKT Stock Price Chart Interactive Chart >


Inhibikase Therapeutics Inc. (IKT) Company Bio


Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.


IKT Latest News Stream


Event/Time News Detail
Loading, please wait...

IKT Latest Social Stream


Loading social stream, please wait...

View Full IKT Social Stream

IKT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!